NO20060865L - Indol-5-YL sulfonamid derivater, deres fremstilling og deres anvedelse 5-HT-6 som modulatorer - Google Patents

Indol-5-YL sulfonamid derivater, deres fremstilling og deres anvedelse 5-HT-6 som modulatorer

Info

Publication number
NO20060865L
NO20060865L NO20060865A NO20060865A NO20060865L NO 20060865 L NO20060865 L NO 20060865L NO 20060865 A NO20060865 A NO 20060865A NO 20060865 A NO20060865 A NO 20060865A NO 20060865 L NO20060865 L NO 20060865L
Authority
NO
Norway
Prior art keywords
preparation
sulfonamide derivatives
indol
modulators
diastereomers
Prior art date
Application number
NO20060865A
Other languages
English (en)
Inventor
Ramon Merce Vidal
Alberto Dordal Zueras
Xavier Codony Soler
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of NO20060865L publication Critical patent/NO20060865L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfmnelse angår nye sulfonamid derivater, med generell formel (la, lb, Ic), eventuelt i form av deres stereoisomerer, fortriimsvis enantiomerer eller diastereomerer, deres racemate, eller i form av en blanding av minst to av deres stereoisomerer, fortrirmsvis enantiomerer eller diastereomerer, i et hvilket som helst blandingsforhold, eller deres salter, fortrirmsvis tilsvarende, fysiologisk akseptable salter, eller tilsvarende solvater; fremgangsmåter for deres fremstilling, deres anvendelse som medikamenter irmen human og/eller veterinær terapi, og de farmasøytiske sammensetningene som irmeholder dem.
NO20060865A 2003-07-30 2006-02-22 Indol-5-YL sulfonamid derivater, deres fremstilling og deres anvedelse 5-HT-6 som modulatorer NO20060865L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301805A ES2222827B1 (es) 2003-07-30 2003-07-30 Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
PCT/EP2004/008511 WO2005013977A1 (en) 2003-07-30 2004-07-29 Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators

Publications (1)

Publication Number Publication Date
NO20060865L true NO20060865L (no) 2006-02-22

Family

ID=34130539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060865A NO20060865L (no) 2003-07-30 2006-02-22 Indol-5-YL sulfonamid derivater, deres fremstilling og deres anvedelse 5-HT-6 som modulatorer

Country Status (22)

Country Link
US (1) US20070032520A1 (no)
EP (1) EP1648445B1 (no)
JP (1) JP2007500165A (no)
KR (1) KR20060066710A (no)
CN (1) CN100558355C (no)
AR (1) AR045156A1 (no)
AT (1) ATE432699T1 (no)
AU (1) AU2004262485A1 (no)
BR (1) BRPI0413110A (no)
CA (1) CA2533976A1 (no)
DE (1) DE602004021384D1 (no)
EC (1) ECSP066325A (no)
ES (2) ES2222827B1 (no)
IL (1) IL172891A0 (no)
MX (1) MXPA06001159A (no)
NO (1) NO20060865L (no)
PE (1) PE20050725A1 (no)
PT (1) PT1648445E (no)
RU (1) RU2006105779A (no)
TW (1) TW200504014A (no)
WO (1) WO2005013977A1 (no)
ZA (1) ZA200600422B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
ES2246721B1 (es) * 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
AU2006209216A1 (en) 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007012284A1 (de) * 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
ATE495737T1 (de) 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
KR101593099B1 (ko) * 2009-10-27 2016-02-11 엘지디스플레이 주식회사 액정표시장치용 어레이 기판 및 그 제조방법
BR112020014561A2 (pt) * 2018-01-17 2020-12-08 Migal - Galilee Research Institute Ltd. Nibidores inovadores da via metabólica da metionina
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US3583622A (en) * 1969-03-21 1971-06-08 Robert Frank Graeff Stapler
US4291486A (en) * 1979-11-30 1981-09-29 Farnam Companies, Inc. Rodent trap
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
MXPA03006605A (es) * 2001-01-30 2003-09-22 Lilly Co Eli Esteres de indol-5-ilo del acido bencensulfonico como antagonistas del receptor 5-ht6.
WO2003027094A2 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
PE20050725A1 (es) 2005-11-16
CA2533976A1 (en) 2005-02-17
IL172891A0 (en) 2006-06-11
ZA200600422B (en) 2007-03-28
ECSP066325A (es) 2006-08-30
RU2006105779A (ru) 2007-09-20
BRPI0413110A (pt) 2006-10-03
TW200504014A (en) 2005-02-01
ES2327847T3 (es) 2009-11-04
MXPA06001159A (es) 2006-04-24
KR20060066710A (ko) 2006-06-16
ATE432699T1 (de) 2009-06-15
EP1648445B1 (en) 2009-06-03
AU2004262485A1 (en) 2005-02-17
ES2222827B1 (es) 2006-03-01
WO2005013977A1 (en) 2005-02-17
JP2007500165A (ja) 2007-01-11
AR045156A1 (es) 2005-10-19
ES2222827A1 (es) 2005-02-01
US20070032520A1 (en) 2007-02-08
PT1648445E (pt) 2009-09-03
CN100558355C (zh) 2009-11-11
DE602004021384D1 (de) 2009-07-16
EP1648445A1 (en) 2006-04-26
CN1832740A (zh) 2006-09-13

Similar Documents

Publication Publication Date Title
NO20060682L (no) Indol-6 sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
NO20060342L (no) 1-sulfonylindol derivater, deres fremstilling og deres andvendelse som 5-HT6 ligander
TW200504014A (en) Indol-5-yl sulfonamide derivatives, their preparation and their use in medicaments
NO20050016L (no) Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
AU2003298094A1 (en) Medicinal arylethanolamine compounds
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
UY27350A1 (es) Azaindoles
NO20092342L (no) Azaspiroderivativater
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20055977L (no) Nye benzimidazolderivater
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
PT1919475E (pt) Derivados de tetrahidro-â-carbolino-sulfonamida de como ligandos de 5-ht6
NO20091766L (no) Spiro-piperidinderivater
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20060155L (no) Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
NO20092149L (no) Spiro-piperidinderivater
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
NO20055492L (no) Anvendelse av sulfonamidderivater for fremstilling av et medikament for profylakse og/eller behandling av lidelser ved matinntak
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
NO20091831L (no) Indoler
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
NO20060506L (no) Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application